Vadadustat: all 39 studies that test it

Page 1 of 1. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.

• Effects of Vadadustat on Anemia, Quality of Life, and Inflammation in Dialysis PatientsNot yet recruitingNCT07537816Phase 4
• Vadadustat for the Treatment of Nonintubated Acute Respiratory Distress Syndrome Due to Pathogen-Associated Lung InjuryRecruitingNCT07086755Phase 2/3
• Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis SubjectsCompletedNCT04707768Phase 3Results posted
• Study to Assess the Safety and Pharmacokinetics of AKB-6548 in Participants With Chronic Kidney Disease (CKD), Stages 3 and 4CompletedNCT04707573Phase 2Results posted
• Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19)CompletedNCT04478071Phase 2Results posted
• Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)CompletedNCT04313153Phase 3Results posted
• Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin AlfaCompletedNCT03799627Phase 2Results posted
• Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Not Receiving ESAs With Anemia Associated With Chronic Kidney Disease in JapanCompletedNCT03461146Phase 3Results posted
• Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Currently Receiving ESAs With Anemia Associated With Chronic Kidney Disease in JapanCompletedNCT03439137Phase 3Results posted
• Efficacy and Safety Study to Evaluate MT-6548 in Peritoneal Dialysis Subjects With Anemia Associated With Chronic Kidney Disease in JapanCompletedNCT03402386Phase 3Results posted
• Efficacy and Safety Study to Evaluate MT-6548 in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease in JapanCompletedNCT03329196Phase 3Results posted
• Study to Evaluate Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating AgentsTerminatedNCT03140722Phase 2Results posted
• Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to Dialysis-Dependent Chronic Kidney Disease (DD-CKD)CompletedNCT03054350Phase 2Results posted
• Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD)CompletedNCT03054337Phase 2Results posted
• Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)CompletedNCT02892149Phase 3Results posted
• Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)CompletedNCT02865850Phase 3Results posted
• Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)CompletedNCT02680574Phase 3Results posted
• Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney DiseaseCompletedNCT02648347Phase 3Results posted
• 16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Participants With End Stage Renal Disease (ESRD) Requiring Chronic HemodialysisCompletedNCT02260193Phase 2Results posted
• 20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and AnemiaCompletedNCT01906489Phase 2Results posted
• 42-Day Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and AnemiaCompletedNCT01381094Phase 2Results posted
• Safety and Efficacy Study for AKB-6548 in Participants With Chronic Kidney Disease and AnemiaCompletedNCT01235936Phase 2Results posted
• To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center HemodialysisCompletedNCT06901505Phase 3
• Vafseo Outcomes In-Center ExperienceActive, not recruitingNCT06520826Phase 3
• Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-Stimulating AgentsWithdrawnNCT05082584Phase 3
• Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney DiseaseWithdrawnNCT05082571Phase 3
• Study in Healthy Adult Subjects to Assess the Effect of Phosphate Binders on the Pharmacokinetics of a Single Dose of VadadustatCompletedNCT04299633Phase 1
• Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney DiseaseCompletedNCT03992066Phase 1
• Drug-Drug Interaction Study of Vadadustat With Digoxin, Adefovir and FurosemideCompletedNCT03801759Phase 1
• Drug-Drug Interaction Study of Vadadustat With Cyclosporine, Probenecid and RifampinCompletedNCT03801746Phase 1
• Drug-Drug Interaction Study of Vadadustat With Rosuvastatin, Sulfasalazine, Pravastatin, Atorvastatin and SimvastatinCompletedNCT03801733Phase 1
• A Single Dose Study of Oral Vadadustat in Subjects With Normal and Impaired Hepatic FunctionCompletedNCT03799848Phase 1
• Study to Evaluate the Effect of Rabeprazole on the Pharmacokinetics of VadadustatCompletedNCT03789032Phase 1
• A Study in Evaluating Bioequivalence of Test and Reference Vadadustat 450 MG and 150 MG Tablets and to Determine Food Effect on the 450 MG TabletCompletedNCT03657290Phase 1
• A Study in Evaluating Bioequivalence Between Test and Reference Formulations of Vadadustat Tablets in Healthy AdultsCompletedNCT03639155Phase 1
• Study to Evaluate Three Times Per Week (TIW) Oral Dosing of Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD)WithdrawnNCT03242967Phase 3
• Effect of AKB-6548 on the Pharmacokinetics of CelecoxibCompletedNCT02502500Phase 1
• Relative Bioavailability of Two Formulations of AKB-6548 and the Food Effect of a New Tablet in Healthy Adult SubjectsCompletedNCT02412449Phase 1
• Effect of AKB-6548 on Cardiac Repolarization Intervals in Healthy VolunteersCompletedNCT02062203Phase 1

← Vadadustat overview